Intelligent Bio Solutions (INBS) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
11 Jun, 2026Business overview and mission
Focuses on intelligent, rapid, non-invasive drug testing solutions to improve quality of life and transform traditional testing methods.
Aims to deliver pain-free, accessible, and cost-effective testing for broad applications.
Technology and product offerings
Intelligent Fingerprinting Drug Screening System uses fingerprint sweat analysis for recent drug use detection, targeting workplace drugs like opiates, cocaine, methamphetamine, and cannabis.
SmarTest Patch is a wearable device for continuous drug monitoring over 7–10 days, detecting a wide range of substances including fentanyl and opioids.
Drug testing process is simple, non-invasive, and delivers results in under 10 minutes, with ongoing validation for even faster results.
Fingerprint testing offers a 16–24 hour detection window, focusing on current impairment rather than historical use.
Competitive advantages
Reduces risk by identifying current impairment, not just past use.
Cost savings by enabling in-house testing and eliminating need for specialized staff.
Ensures privacy, dignity, and testing integrity with administrator-supervised, self-locking sample seals.
Outperforms urine and saliva tests in speed, cost, and convenience, with up to 99% accuracy.
Latest events from Intelligent Bio Solutions
- Fingertip sweat drug test offers rapid, real-time workplace screening with high margins and global growth.INBS
Planet MicroCap Las Vegas 202617 Jun 2026 - Non-invasive fingerprint drug testing drives growth, efficiency, and global market expansion.INBS
Investor presentation17 Jun 2026 - Revenue up 148% year-over-year, net loss narrowed, and cash reserves strengthened.INBS
Q4 202411 Jun 2026 - Gross margin surged as cartridge sales grew, but liquidity concerns remain without new funding.INBS
Q2 202511 Jun 2026 - Gross margin and profit surged on cartridge sales, but liquidity and funding risks persist.INBS
Q3 202511 Jun 2026 - Revenue up 10% year-over-year, but higher R&D costs widened net loss and increased risk.INBS
Q1 202511 Jun 2026 - Flexible $100M shelf registration supports growth in rapid diagnostics and US market entry.INBS
Registration filing11 Jun 2026 - Q2 revenue up 48% year-over-year, gross margin at 49%, but liquidity risks persist.INBS
Q2 202611 Jun 2026 - Revenue grew 16% year-over-year in Q4, with FDA clearance progress and global expansion ongoing.INBS
Q4 202511 Jun 2026